An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate Cancer

Inclusion Criteria:

* Patient is male and aged \> 18 years old
* History of localized adenocarcinoma of the prostate status post (s/p) radical prostatectomy
* An initial elevated PSA \>= 0.2 followed by a subsequent confirmatory PSA \>= 0.2 clinically suspicious for biochemically recurrent disease
* If the patients were previously taking androgen deprivation therapy (ADT), it should be discontinued at least 12 weeks prior to the study
* Treatment plan includes salvage radiation with or without hormones.
* Patient willing to provide signed informed consent and willing to comply with all required study schedule events, where safe and feasible
* Non-English speaking patients may be enrolled.

Exclusion Criteria:

* Patients with any medical condition or circumstance that the investigator believes may compromise the data collected or lead to a failure to fulfil the study requirements
* Patients who are planned to have an Iodinated contrast agent with computed tomography (CT) or gadolinium based contrast agent with MRI or other PET radiotracer \< 24 hours prior to the PET scan
* Patients with contraindication to undergo MRI
* Patients with extreme claustrophobia
* Patients with prior allergy to MRI contrast agent
* Patients who are cognitively impaired